maculopapular lesions over the face, neck, trunk, flexural areas and upper extremities [ Figure 1 ] which were firm to rubbery in consistency. Six months later he was admitted to a tertiary care hospital with frontal headache, projectile vomitings and left sided weakness. Hemiparesis, polydipsia and polyuria were evident. Nail, hair and mucous membrane examination did not reveal any abnormality. His medical and family history was otherwise unremarkable.
INTRODUCTION
J uvenile xanthogranulomas (JXG) are benign tumors of histiocytic cells that are usually limited to skin, occurring predominantly in infancy and early childhood with usual spontaneous regression. Histologically, JXG is composed of collections of foamy histiocytes and Touton giant cells with a distinct immunohistochemistry (IHC) staining pattern (positive CD68, alpha-1-antitrypsin, factor XIIIa and lysozyme; S100 and CD1a -negative). [1] Systemic JXG is rare, and extracutaneous involvement usually includes eyes, lung, liver, spleen, and central nervous system (CNS) . Although there are some reports on intracranial involvement, [2] [3] [4] occurrence of multiple brain lesions and relapsing cutaneous lesions after chemotherapy is extremely rare.
CASE REPORT
Three and a half year old boy suffered from numerous, asymptomatic well demarcated, yellowish Figure 2 ]. Further diagnostic workup for detecting possible systemic involvement at other sites such as hematological and biochemical parameters including lipid profile, ophthalmological checkup, abdominal ultrasound, skeletal survey, chest X-ray, cerebrospinal fluid examination, bone marrow aspiration and biopsy were performed and did not show any abnormality.
Skin lesion biopsy showed epidermal atrophy, focal infiltrates of foamy histiocytes and macrophages; few Touton type giant cells and mild infiltration by lymphocytes and eosinophils in the dermis. Histopathologic examination of the brain biopsy showed diffuse infiltrates with sheets of histiocytic cells and occasional giant cells consistent with the dermal specimen. IHC labeling of both the specimens revealed CD68-positive and CD1a-negative cells [ Figure 3 ]. This extensive diagnostic workup along with clinical correlation confirmed the diagnosis of JXG involving skin and brain in a multifocal manner. The patient was treated by oncologist with Langerhans cell histiocytosis-III (LCH) chemotherapy protocol comprising of induction with methotrexate, vinblastine and prednisolone followed by addition of 6-mercaptopurine and oral weekly methotrexate in maintenance phase over a period of 2 years. Desmopressin puffs were administered for diabetes insipidus. Cutaneous lesions showed good clinical response and healed with mild atrophic scarring. The follow-up MRI brain scans taken at the completion of treatment showed gradual regression of all lesions [ Figure 4 ]. However, 6 months after completion of chemotherapy he developed similar cutaneous lesions which were confirmed histologically as JXG. A repeat MRI brain revealed no significant change as compared to previous postchemotherapy scan. Further diagnostic workup for detecting possible new systemic involvement at other sites was performed and was unremarkable. So a diagnosis of JXG with cutaneous relapse postchemotherapy was made.
At present patient is showing normal growth and mental development and is being conservatively managed with regular follow-ups as no new systemic involvement was detected. 
DISCUSSION
JXG is one of the most common non-LCH in children. [4] In 1954, JXG was placed under non-Langerhans histiocytosis group as an archetype of non-Langerhans histiocytosis with factor XIIIa+ dermal dendrocytes as the strongest candidate originating cells; however, this concept has been challenged recently and plasmacytoid monocyte has been proposed as the putative origin of JXG. [5] The cutaneous presentation consists of two main clinical forms: Papular and Nodular. The papular form as in our case is characterized by numerous asymptomatic firm, yellowish hemispheric lesions 2-5 mm in diameter located mainly in the upper part of the body. They are usually believed to be benign and regress spontaneously leaving a flat, atrophic scar or an area of altered pigmentation. An extremely rare extracutaneous manifestation of the papular variant is CNS involvement. [6] The pathological changes in the brain may originate from mesenchymal stem cells of the dura mater, from the intracerebral perivascular soft tunica vaginalis or the wall of brain vessels themselves. The lesions can be solitary or multiple. In CNS involvement, JXG can induce epilepsy, mental and growth retardation, diabetes insipidus, ataxia, and hemiplegia. According to the literature, JXG appears in the CNS either secondary to the skin, soft tissues, lung and pancreas which have been involved for several months or years or rarely as a primary manifestation. [7] In our case, cutaneous lesions were present 6 months before the occurrence of hemiplegia and diabetes insipidus.
Although systemic JXG without organ damage can have a benign course, CNS disease may be difficult to treat and is associated with severe morbidity and mortality. [4] In a review of 26 patients with CNS JXG, a variety of chemotherapy, radiotherapy, surgery or immunosuppressive therapies or combinations of these modalities have been used to treat these patients. [8] Patients with systemic JXG have fared well with LCH-based chemotherapy because both LCH and JXG are dendritic cell-related disorders. [9] The inclusion of a vinca alkaloid and steroid is associated with better overall response rate. [10] Our patient had JXG with disseminated CNS involvement and appeared to have had a good response to LCH-based regimens that included induction with both corticosteroids and vinca alkaloids, with resolution of the brain lesions. As to whether the recurrence of cutaneous but not CNS lesions till date after stopping chemotherapy suggests a resistant form of the cutaneous disease is an enigma.
Although CNS involvement is rare, a high degree of clinical suspicion is warranted when patients present with a papular variant of JXG. A baseline MRI brain can help to rule out CNS involvement. An abnormality if found should warrant further investigations and involvement of concerned specialties.
Overall, our knowledge of systemic JXG is still very limited; more experience in its diagnosis and treatment is necessary and expected because of the low, but potentially serious risk of internal organ involvement. More individual cases reports and multicenter coordination should be encouraged.
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